Ozanimod

• CAT Number: I001173
• CAS Number: 1306760-87-1
• Molecular Formula: C₂₃H₂₄N₄O₃
• Molecular Weight: 404.46
• Purity: 98%
• Synonyms: Ozanimod; RPC1063;(S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile
• Target: S1PR1
• Target Protein: P21453
• Solubility: DMSO: ≥ 29 mg/mL
• Appearance: Solid
• Storage: Dry, dark and at 2 - 8 °C for six months or -20°C for two years.
• IC50: S1PR1:1.03 nM (EC50)
• IUPAC Name: 5-[3-[(1S)-1-(2-hydroxyethylamino)-2,3-dihydro-1H-inden-4-yl]-1,2,4-oxadiazol-5-yl]-2-propan-2-yloxybenzonitrile
• InChI: InChI=1S/C23H24N4O3/c1-14(2)29-21-9-6-15(12-16(21)13-24)23-26-22(27-30-23)19-5-3-4-18-17(19)7-8-20(18)25-10-11-28/h3-6,9,12,14,20,25,28H,7-8,10-11H2,1-2H3/t20-/m0/s1
• InChIKey: XRVDGNKRPOAQTN-FQEVSTJZSA-N
• SMILES: CC(C)OC1=C(C=C(C=C1)C2=NC(=NO2)C3=C4CC[C@@H](C4=CC=C3)NCCO)C#N

Ozanimod（Cat No.:I001173）is a selective sphingosine 1-phosphate (S1P) receptor modulator used for treating relapsing forms of multiple sclerosis and ulcerative colitis. By binding to S1P receptors, Ozanimod reduces the migration of lymphocytes into the central nervous system and inflamed tissues, thereby decreasing immune-mediated damage. Its oral administration and receptor selectivity result in fewer immune cells in circulation, helping to manage inflammation while preserving immune function. Ozanimod offers an effective and convenient therapy for patients, reducing relapse rates and slowing disease progression in autoimmune conditions.